Journal Article

Consensus of Chinese experts on glioma multidisciplinary team management (2nd edition)

Luo, Xufei, Wu, Jinsong, Li, Ming, Mao, Ying, Zhou, Zhirui, Chen, Yaolong, Yin, Siyuan, Tang, Zhiwei, Zhao, Guoguang, Jiang, Tao, Wu, Zanyi, Wang, Ling

2024

Overview

The efficacy and follow-up should be evaluated regularly, and the plan should be dynamically adjusted by the MDT expert group if necessary, aiming to provide glioma patients with the best standardized, individualized, and comprehensive health care services. Standardize the diagnosis and treatment strategy of glioma through MDT, shorten the time, reduce the cost, increase the efficiency, enhance the ability and level of medical institutions, improve patients’ quality of life, and prolong the overall survival. The establishment of a tertiary diagnosis and treatment system should follow the principle of patient voluntariness to coordinate resource allocation, optimize the utilization of medical resources, reduce costs, and promote the development of medical and health care systems. Evidence recommenders should use the drug in an off-label manner based on the following implementation process: (1) after discussion and voting by the MDT, key technical points of off-label drug use are clarified, especially the administration, dosage, and course of treatment; after two-third or more of the participating experts vote to agree, the MDT secretary submits an application to the Pharmaceutical Affairs Committee, attaching the MDT decisions, supporting evidence, and providing clarified authority for off-label use; (2) announcement of the approval of the Pharmaceutical Affairs Committee; (3) implementation in the Department of Pharmacy (including pharmacy remarks, adjustment of prescription review rules, and dispensing warnings); and (4) authorization of the physicians in-charge to prescribe to patients and be responsible for observing and monitoring safety and efficacy and providing timely feedback to the MDT.

• Publisher: Lippincott Williams & Wilkins,Lippincott Williams & Wilkins Ovid Technologies,Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China%Department of Radiation Oncology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China%Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China%Neurosurgery Department, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China%Department of Neurosurgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan 463599, China%State Key Laboratory of Pharmaceutical Biotechnology, Institute for Brain Sciences, Advanced Institute for Life Sciences, School of Life Sciences, Nanjing University, Nanjing, Jiangsu 210023, China%Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, China%School of Public Health, Lanzhou University, Lanzhou, Gansu 730000, China%Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China%Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China,Wolters Kluwer
• Subject: Archives & records / Brain Neoplasms - therapy / China / Clinical decision making / Clinical outcomes / Clinical trials / Consensus / Consensus Statement / Departments / Drug dosages / Drug use / East Asian People / Genetic counseling / Glioma / Glioma - therapy / Hematology / Hospitals / Humans / Laboratories / Medical diagnosis / Medical imaging / Medical prognosis / Medical records / Multidisciplinary teams / Neurosurgery / Oncology / Pathology / Patient Care Team / Patients / Pharmaceuticals / Pharmacy / Physicians / Quality standards / Radiation therapy / Survival analysis